Table II.

Both R. sphaeroides LPS and anti-hTLR4-IgA Ab up-regulate CRISPLD2 secretion and reduce E. coli LPS-induced TNF-α and IL-6 production

TreatmentaConcentration (μg/ml)CRISPLD2b (μg/ml)TNF-αb (ng/ml)IL-6b (ng/ml)
Controlc0.37 ± 0.100.04 ± 0.010.11 ± 0.02
E. coli LPS11.59 ± 0.268.56 ± 0.6210.5 ± 0.28
R. sphaeroides LPS11.40 ± 0.063.45 ± 0.27d7.98 ± 0.22d
E. coli LPS + R. sphaeroides LPS1 + 11.65 ± 0.093.29 ± 0.07d7.25 ± 0.59d
Anti-hTLR4-IgA11.66 ± 0.040.08 ± 0.030.11 ± 0.03
Anti-hTLR4-IgA51.93 ± 0.210.13 ± 0.010.07 ± 0.03
E. coli LPS + anti-hTLR4-IgA1 + 12.25 ± 0.24e3.17 ± 0.09d7.06 ± 0.45d
E. coli LPS + anti-hTLR4-IgA1 + 52.55 ± 0.43e2.63 ± 0.07d5.27 ± 0.68d
  • a Human PBMCs were treated by the reagents as indicated in table for 12 h.

  • b CRISPLD2, TNF-α, and IL-6 were measured by ELISA in culture supernatants.

  • c Ten microliters of PBS was added in culture as control. Data (mean ± SD of triplicate wells) are from two independent experiments.

  • d Value of p < 0.005 as compared with that from E. coli LPS treatment alone.

  • e Value p < 0.05 as compared with that from E. coli LPS treatment alone.